News & Updates

Rivaroxaban a game-changer for acute LV thrombus post-MI

15 May 2025 by

Patients who develop an acute thrombus in the left ventricle (LV) following myocardial infarction (MI) fare equally well when treated with rivaroxaban as they do with warfarin, as shown in the RIVAWAR study.

Rivaroxaban a game-changer for acute LV thrombus post-MI

15 May 2025

Up-to-date tetanus shots lessen disease severity, improve survival outcomes

15 May 2025

Complete childhood vaccinations help reduce the risk of mortality in adult patients with tetanus, according to a study.

Up-to-date tetanus shots lessen disease severity, improve survival outcomes

15 May 2025

First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression

15 May 2025 by

First-line treatment with tislelizumab plus chemotherapy showed better survival outcomes and response among patients with locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC), particularly those with high PD-L1 expression, compared with chemotherapy alone, according to a subgroup analysis of the phase III RATIONALE-304 trial presented at ELCC 2025.

First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression

15 May 2025

AML treatment efficacy varies by status, age, cytogenetic risk

14 May 2025

Some of the important treatment options for patients with acute myeloid leukaemia (AML) include chemotherapy, targeted therapy, and immunotherapy, but the efficacy of these treatments may vary depending on AML status, age, and cytogenetic risk, according to a study.

AML treatment efficacy varies by status, age, cytogenetic risk

14 May 2025

EGFR-related skin AE rates drop with COCOON regimen

14 May 2025 by

Interim data from the phase II COCOON trial demonstrate the potential of the COCOON dermatologic management (DM) regimen to significantly reduce the incidence and severity of dermatologic adverse events (dAEs) tied to amivantamab plus lazertinib treatment in patients with EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC).

EGFR-related skin AE rates drop with COCOON regimen

14 May 2025

ACE-I/ARB use helps avert death in cirrhosis patients

13 May 2025

Exposure to angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) may prevent mortality among patients with cirrhosis, a study has shown.

ACE-I/ARB use helps avert death in cirrhosis patients

13 May 2025

TAF prophylaxis prevents mother-to-child transmission of HBV

13 May 2025

Treatment with tenofovir alafenamide (TAF) is generally safe and effective for the prevention of hepatitis B virus (HBV) mother-to-child transmission (MTCT), reports a study, noting that the expected 8-week prenatal duration is feasible.

TAF prophylaxis prevents mother-to-child transmission of HBV

13 May 2025

MIRASOL final analysis: MIRV remains superior to chemo for ovarian cancer

13 May 2025 by

In the final overall survival (OS) analysis of the phase III MIRASOL trial, the survival benefit previously reported with the antibody drug conjugate mirvetuximab soravtansine (MIRV) remains superior to investigator’s choice chemotherapy (ICC) for the treatment of folate receptor alpha-positive, platinum-resistant ovarian cancer (FRα+ PROC).

MIRASOL final analysis: MIRV remains superior to chemo for ovarian cancer

13 May 2025

Long-term use of antidepressants linked to sudden cardiac death

13 May 2025 by

New research presented at EHRA 2025 has shown that patients who have taken antidepressants for extended periods are at increased risk of sudden cardiac death.

Long-term use of antidepressants linked to sudden cardiac death

13 May 2025

Another win for semaglutide: Improved outcomes in MASH with fibrosis

12 May 2025 by

Semaglutide may also confer hepatoprotective benefits, with interim efficacy data from the ongoing phase III ESSENCE study showing that the glucagon-like peptide-1 (GLP-1) receptor agonist helps dial down disease activity in patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate-to-severe fibrosis.

Another win for semaglutide: Improved outcomes in MASH with fibrosis

12 May 2025

News & Updates

Filter by Specialty:

Specialty:

Rivaroxaban a game-changer for acute LV thrombus post-MI

Rivaroxaban a game-changer for acute LV thrombus post-MI

Up-to-date tetanus shots lessen disease severity, improve survival outcomes

Up-to-date tetanus shots lessen disease severity, improve survival outcomes

First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression

First-line tislelizumab plus chemo shows benefit in nsq-NSCLC with high PD-L1 expression

AML treatment efficacy varies by status, age, cytogenetic risk

AML treatment efficacy varies by status, age, cytogenetic risk

EGFR-related skin AE rates drop with COCOON regimen

EGFR-related skin AE rates drop with COCOON regimen

ACE-I/ARB use helps avert death in cirrhosis patients

ACE-I/ARB use helps avert death in cirrhosis patients

TAF prophylaxis prevents mother-to-child transmission of HBV

TAF prophylaxis prevents mother-to-child transmission of HBV

MIRASOL final analysis: MIRV remains superior to chemo for ovarian cancer

MIRASOL final analysis: MIRV remains superior to chemo for ovarian cancer

Long-term use of antidepressants linked to sudden cardiac death

Long-term use of antidepressants linked to sudden cardiac death

Another win for semaglutide: Improved outcomes in MASH with fibrosis

Another win for semaglutide: Improved outcomes in MASH with fibrosis